A61K 38/191
Tumor necrosis factors [tnf]
Official title: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
A61K38/191 (Tumor necrosis factors [tnf]) appears on 696 US grants and 1,171 published applications in this corpus.
Search patents in A61K- Granted patents
- 696
- Published applications
- 1,171
- Assignees
- 534
- Inventors
- 1,841
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 6 | 0 |
| 1991 | 1 | 0 |
| 1992 | 13 | 0 |
| 1993 | 18 | 0 |
| 1994 | 14 | 0 |
| 1995 | 5 | 0 |
| 1996 | 6 | 0 |
| 1997 | 10 | 0 |
| 1998 | 11 | 0 |
| 1999 | 9 | 0 |
| 2000 | 11 | 0 |
| 2001 | 14 | 11 |
| 2002 | 9 | 34 |
| 2003 | 12 | 33 |
| 2004 | 10 | 27 |
| 2005 | 4 | 41 |
| 2006 | 13 | 35 |
| 2007 | 13 | 42 |
| 2008 | 10 | 37 |
| 2009 | 15 | 48 |
| 2010 | 23 | 49 |
| 2011 | 17 | 54 |
| 2012 | 24 | 37 |
| 2013 | 21 | 52 |
| 2014 | 27 | 78 |
| 2015 | 40 | 67 |
| 2016 | 46 | 53 |
| 2017 | 54 | 52 |
| 2018 | 31 | 55 |
| 2019 | 43 | 71 |
| 2020 | 31 | 48 |
| 2021 | 27 | 65 |
| 2022 | 21 | 51 |
| 2023 | 15 | 36 |
| 2024 | 24 | 37 |
| 2025 | 24 | 34 |
| 2026 | 15 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TNFR2 agonists with improved stability15 Sep 2026US 12,735,472 B2Universität Stuttgart
- Compositions comprising a tweak ligand and methods of using same25 Aug 2026US 12,714,740 B2Children's Hospital Medical Center
- Light-induced cellular production of immune functional extracellular vesicles25 Aug 2026US 12,714,751 B2University of Florida Research Foundation, Inc.
- Compositions and methods for inhibiting the biological activity of soluble biomolecules21 Jul 2026US 12,685,758 B2NaNotics, LLC
- Targeting lung-resident TNFR2+ cDC2 (R2D2) subpopulation to treat asthma14 Jul 2026US 12,678,487 B2University of Florida Research Foundation, Inc.
- Oncolytic virus therapy1 Oct 2026US 2026/0294987 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- 3-(sulphonyl or sulfonimidoyl)prop-2-en-1-yl]-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives27 Aug 2026US 2026/0250250 A1
- Composition including virus like particles (vlps), a kit, and method for antitumoral therapy13 Aug 2026US 2026/0234573 A1Cnpem- Centro Nacional De Pesquisa Em Energia E Materiais
- Certain aryl pladienolide compounds and methods of use6 Aug 2026US 2026/0224560 A1Eisai R&D Management Co., Ltd.
- Use of a composition comprising a neo-synthesized extracelllar matrix for the treatment of cancer, in particular for the inhibition of cancer viability, migration, and proliferation6 Aug 2026US 2026/0224632 A1Novadip Biosciences
Most cited
By later US patents
- Composition and method for delivery of biologically-active factors209US 6,274,552 B1CytImmune Sciences, Inc. · 2001
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Metabolically activated recombinant viral vectors and methods for the preparation and use163US 6,596,535 B1Targeted Genetics Corporation · 2003